Evidence map›Paper›PMID 39684739›Full record

ArticleInternational journal of molecular sciences2024

Rapid LC-MS/MS Evaluation of Collagen and Elastin Crosslinks in Human and Mouse Lung Tissue with a Novel Bioanalytical Surrogate Matrix Approach.

Sarah M Lloyd, Elizabeth J Sande, Kenneth Ruterbories, Stephen P O'Brien, Yue-Ting Wang, Lucy A Phillips, Tracy L Carr, Meghan Clements, Lisa A Hazelwood, Yu Tian and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah M LloydAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.ORCID 0000-0001-6197-1482
Elizabeth J SandeAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
Kenneth RuterboriesAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
Stephen P O'BrienAbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.
Yue-Ting WangAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
Lucy A PhillipsAbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.
Tracy L CarrAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
Meghan ClementsAbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.
Lisa A HazelwoodAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
Yu TianAbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.ORCID 0000-0003-3754-5875
Yupeng HeAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
Qin C JiAbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations to post-translational crosslinking modifications in the extracellular matrix (ECM) are known to drive the pathogenesis of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Thus, the methodology for measuring crosslinking dynamics is valuable for understanding disease progression. The existing crosslinking analysis sample preparation and liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are typically labor-intensive and time-consuming which limits throughput. We, therefore, developed a rapid approach minimizing specialized equipment and hands-on time. The LC-MS/MS sample analysis time was reduced to two minutes per sample. We then improved the analytical integrity of the method by developing a novel surrogate matrix approach for the dihydroxylysinonorleucine (DHLNL) crosslink. By modifying sample preparation, we prepared a tissue-based surrogate matrix with undetectable levels of endogenous DHLNL, providing a strategy for quantifying this crosslink with a more relevant standard matrix. We then applied this rapid methodology to evaluating crosslinking in lung fibrosis. We showed an increase in DHLNL in human IPF lung relative to healthy donors, as well as in a fibrotic mouse model. Finally, we demonstrated that this increase in DHLNL could be mitigated with an anti-fibrotic compound, suggesting that this assay has potential for evaluating pharmaceutical compound efficacy.

Indexed as

CollagenElastinLungTandem Mass SpectrometryAnimalsChromatography, LiquidCross-Linking ReagentsExtracellular MatrixHumansIdiopathic Pulmonary FibrosisLiquid Chromatography-Mass SpectrometryMaleMiceMice, Inbred C57BLCollagenCross-Linking ReagentsElastinbioanalysiscollagencrosslinkingelastinfibrosisLC-MS/MSlungsurrogate matrix

Identifiers

PMID39684739
PMCPMC11641751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.